Details of adverse reactions and side effects of Dacomitinib/Dozerun

Dacomitinib/Dacomitinib (Dacomitinib) is a second-generation irreversible EGFR tyrosine kinase inhibitor, mainly used to treat patients with advanced or metastatic non-small cell lung cancer who carry EGFR sensitive mutations. Its pharmacological effect is through irreversible binding to EGFR and blocking signaling pathways, thereby inhibiting the proliferation and survival of cancer cells and providing targeted treatment options for patients. Despite its remarkable efficacy, dacomitinib may still cause a series of adverse reactions during use. Understanding these side effects can help patients manage their treatment and life rationally.

Clinical observations show that the most common adverse reactions of dacomitinib include rash, stomatitis, diarrhea, onychomycosis and dry eye. These side effects are closely related to the mechanism of drug inhibition of EGFR, because EGFR not only exists in cancer cells, but is also involved in the physiological regulation of skin, intestines and hair follicles. The rash usually appears on the face, chest, and back and is mostly mild to moderate, but some patients may experience pain or itching and require intervention with topical moisturizers or low-intensity topical medications. Diarrhea and stomatitis are common in the early stages of medication and can be effectively relieved through regular diet, fluid rehydration and local care.

In addition, dacomitinib may cause weight loss, fatigue, decreased appetite and a slight increase in blood pressure. Some patients may also experience an increase in liver function indicators, such asan increase in ALT and AST. Therefore, blood routine, liver function and blood pressure should be monitored regularly during medication, abnormalities should be detected in a timely manner and the dosage should be adjusted under the guidance of a doctor. For patients taking long-term medication, early intervention and lifestyle management (such as a low-irritation diet, keeping the skin clean and moisturized) can significantly reduce the impact of side effects on daily life.

Generally speaking, the side effects of dacomitinib are mostly controllable and can usually be managed through dose adjustment, symptomatic treatment, and regular follow-up.

Reference materials:https://www.pfizer.com/products/product-detail/vizimpro